Merck Welireg (belzutifan by Quarter

Name: Merck Welireg (belzutifan by Quarter (MRK)
Creator: Merck

Welireg (belzutifan — HIF-2α inhibitor) — U.S. reported growth YoY (%) (%)

Quarterly Annual

Merck Welireg (belzutifan: 55.0% in Q2 2026, up 36.0 pts from a year earlier.

Latest, Q2 2026

55.0%

Period ended Jun 30, 2026

Change on a year earlier

+36.0 pts

19.0% in Q2 2025

History

9 quarters

Since Q1 2024

Sources

Documents cited below

Where the Q2 2026 figure comes from

“|| Welireg | 271 | 162 | 67 | 214 | 138 | 55 | 57 | 24 | 133”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Welireg (belzutifan — HIF-2α inhibitor) — U.S. reported growth YoY (%) (%)	Year on year	Source
Q2 2026	Jun 30, 2026	55.0%	+36.0 pts	Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025	Dec 31, 2025	24.0%	-90.0 pts	Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025	Sep 30, 2025	27.0%	-121.0 pts	Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025	Jun 30, 2025	19.0%	-119.0 pts	Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025	Mar 31, 2025	59.0%	-30.0 pts	Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024	Dec 31, 2024	114.0%	–	Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024	Sep 30, 2024	148.0%	–	Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2024	Jun 30, 2024	138.0%	–	Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024	Mar 31, 2024	89.0%	–	Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗

Cite this data

StockData. (2026). Merck Welireg (belzutifan (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-welireg-us-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.